Based in the Angolan capital of Luanda, on Africa’s southwest coast, FoodCare is a dried food manufacturer that processes and ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

Cassava Sciences, Inc.’s SAVA share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...

Based in the Angolan capital of Luanda, on Africa’s southwest coast, FoodCare is a dried food manufacturer that processes and packages a range of 25 homegrown foods, including cassava ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...